Condition: IgAN · C3G · Complement-mediated Kidney Disease · Sponsor: ADARx Pharmaceuticals, Inc.
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
This description comes directly from the study's public registry record.
Tracy Nguyen · 877-232-7974 · info@adarx.com
Always discuss trial participation with your own doctor first.
| ADARx Clinical Site | Doral, Florida, United States | Recruiting |
| ADARx Clinical Site | Miami, Florida, United States | Recruiting |
| ADARx Clinical Site | Pembroke Pines, Florida, United States | Recruiting |
| ADARx Clinical Site | Iowa City, Iowa, United States | Recruiting |
| ADARx Clinical Site | Shreveport, Louisiana, United States | Recruiting |
| ADARx Clinical Site | Shelby, Michigan, United States | Recruiting |
| ADARx Clinical Site | Great Neck, New York, United States | Recruiting |
| ADARx Clinical Site | Columbus, Ohio, United States | Recruiting |
| ADARx Clinical Site | Dakota Dunes, South Dakota, United States | Recruiting |
| ADARx Clinical Site | Dallas, Texas, United States | Recruiting |
| ADARx Clinical Site | Houston, Texas, United States | Recruiting |
| ADARx Clinical Site | Liverpool, New South Wales, Australia | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06989359